BofA analyst Geoff Meacham raised the firm’s price target on Bristol-Myers to $85 from $82 and keeps a Buy rating on the shares. The firm’s forecast is in-line with consensus on Q1 revenue and "modestly above" consensus on EPS, the analyst. noted. Q1 is seasonally a weaker quarter in Biopharma and for the group generally BofA expects an in-line quarter and for the outlook to be "solid."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Legend Biotech price target raised to $77 from $66 at H.C. Wainwright
- Legend Biotech CARTITUDE-4 data ‘highly impressive,’ says Guggenheim
- COWZ ETF: A Cash Cow for Your Portfolio
- Juno Therapeutics’ lisocabtagene maraleucel receives FDA orphan designation
- Bristol-Myers’ Juno get orphan designation for lisocabtagene maraleucel